Search Within

Mary Ellen Moynahan

Formats
  1. Journal Article (56)
  2. Meeting Abstract (46)
  3. Conference Paper (2)
  4. Book Section (1)
Groups
  1. Breast Medicine Service (105)
  2. Department of Medicine (105)
  3. Solid Tumor Oncology Division (105)
  4. Survivorship Research (59)
  5. GSK Faculty (52)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (49)

More Groups

People
  1. Clifford Hudis (54)
  2. Larry Norton (38)
  3. Maria Jasin (30)
  4. Andrew Seidman (28)
  5. Teresa Gilewski (26)
  6. Gabriella D'Andrea-Carlino (25)

More People

Years
  1. 2020 (1)
  2. 2019 (1)
  3. 2018 (2)
  4. 2017 (2)
  5. 2016 (9)
  6. 2015 (10)

More Years

Publications
  1. Journal of Clinical Oncology (27)
  2. Cancer Research (14)
  3. Breast Cancer Research and Treatment (12)
  4. Clinical Cancer Research (8)
  5. Proceedings of the National Academy of Sciences of the United States of America (4)
  6. Clinical Breast Cancer (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (27)
  2. American Association for Cancer Research (23)
  3. Springer (12)
  4. Elsevier Inc. (11)
  5. Nature Publishing Group (5)
  6. Cell Press (4)

More Publishers

Results (105)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis
    Journal Article

    Moynahan, M. E.; Jasin, M.
    Nature Reviews Molecular Cell Biology (2010)

    Fulltext@MSK | Save
  • Loss of 53BP1 is a gain for BRCA1 mutant cells
    Journal Article

    Kass, E. M.; Moynahan, M. E.; Jasin, M.
    Cancer Cell (2010)

    Fulltext@MSK | Save
  • Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)
    Meeting Abstract

    Conlin, A. K.; Hudis, C. A.; Bach, A.; Moynahan, M.; Lake, D.; Forero-Torres, A.; Wright, G.; Hackney, M.; Clawson, A.; Seidman, A. D.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • PIK3CA and AKT1 mutations are independent in invasive breast cancer
    Meeting Abstract

    Moynahan, M. E.; Heguy, A.; Drobnjak, M.; Traina, T.; Howard, J.; Patil, S.; Gerald, W.; Solit, D.; Hudis, C.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma
    Journal Article

    Sugarman, S.; Wasserheit, C.; Hodgman, E.; Coglianese, M.; D'alessandro, A.; Fornier, M.; Troso-Sandoval, T.; D'Andrea, G.; Drullinsky, P.; Lake, D.; more...
    Breast Cancer Research and Treatment (2009)

    Fulltext@MSK | Save
  • PIK3CA mutation associates with improved outcome in breast cancer
    Journal Article

    Kalinsky, K.; Jacks, L.; Heguy, A.; Patil, S.; Drobnjak, M.; Bhanot, U. K.; Hedvat, C. V.; Traina, T. A.; Solit, D.; Gerald, W.; more...
    Clinical Cancer Research (2009)

    Fulltext@MSK | Save
  • Nanoparticle albumin-bound paclitaxel in 3 dosing schedules with bevacizumab as first line therapy for HER2-negative metastatic breast cancer: An interim safety analysis
    Meeting Abstract

    Seidman, A. D.; Conlin, A. K.; Moynahan, M. E.; Bach, A.; Troso-Sandoval, T.; Sugarman, S.; Forero, A.; Kerr, R.; Wright, G.; Hudis, C. A.
    EJC Supplements (2008)

    Fulltext@MSK | Save
  • The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Journal Article

    Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible
    Journal Article

    Dang, C.; D'Andrea, G.; Lake, D.; Sugarman, S.; Fornier, M.; Moynahan, M. E.; Gilewski, T.; Hurria, A.; Mills, N.; Troso-Sandoval, T.; more...
    Clinical Breast Cancer (2008)

    Fulltext@MSK | Save
  • Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report
    Meeting Abstract

    Conlin, A. K.; Seidman, A. D.; Moynahan, M. E.; Traina, T.; Mace, J. R.; Meiri, E.; Bach, A.; Edwards, C.; Hudis, C. A.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save